表紙:終末糖化産物(AGEs)の市場規模:タイプ別(非蛍光、蛍光)、用途、エンドユーザー、地域別、シェア、見通し、および機会分析(2020年~2027年)
市場調査レポート
商品コード
980034

終末糖化産物(AGEs)の市場規模:タイプ別(非蛍光、蛍光)、用途、エンドユーザー、地域別、シェア、見通し、および機会分析(2020年~2027年)

Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs and Fluorescent AGEs ), by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 105 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.03円
終末糖化産物(AGEs)の市場規模:タイプ別(非蛍光、蛍光)、用途、エンドユーザー、地域別、シェア、見通し、および機会分析(2020年~2027年)
出版日: 2020年12月28日
発行: Coherent Market Insights
ページ情報: 英文 105 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

2016年のThe American Heart Associationの報告によると、世界における心血管疾患(CVD)が毎年1,730万人の死亡原因となっており、2030年までに2,330万人がCVDで死亡すると予測されています。このような慢性疾患の有病率の上昇は、予測期間中に終末糖化産物市場の成長を牽引すると予測されています。

市場関係者は、糖尿病合併症における終末糖化産物(AGEs)が糖尿病合併症における代謝記憶の発達の鍵となる因子であることから、糖尿病合併症における終末糖化産物の研究開発に力を入れており、予測期間における市場成長を牽引するものと期待されています。

当レポートは、世界の終末糖化産物(AGEs)市場について調査しており、市場規模やシェア、機会や動向、成長および抑制要因、タイプ・用途・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場の展望

  • レポートの概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場内訳:タイプ別
    • 市場内訳:用途別
    • 市場内訳:流通チャネル別
    • 市場内訳:地域別
  • Coherent Opportunity Map (COM)

第3章 市場力学、規制、および動向分析

  • 市場力学
    • 成長要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 主な発展
  • PEST分析

第4章 COVID-19パンデミックの影響

  • インパクト調査
  • COVID-19以前の市場シナリオ
  • COVID-19後の市場シナリオ
  • COVID-19に対する政府の措置

第5章 市場分析:タイプ別(2016-2027)

  • イントロダクション
  • 非蛍光AGEs
  • 蛍光AGEs

第6章 市場分析:用途別(2016-2027)

  • イントロダクション
  • 糖尿病合併症
  • 骨の疾患
  • 神経変性疾患
  • その他

第7章 市場分析:エンドユーザー別(2016-2027)

  • イントロダクション
  • 病院
  • 専門クリニック
  • 在宅ケア

第8章 市場分析:地域別(2016-2027)

  • イントロダクション
  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第9章 競合情勢

  • ヒートマップ分析
  • 市場シェア分析
    • Merck KGaA
    • Device Portfolio
    • Diagnoptics Technologies BV
    • Device Portfolio
    • Cell Biolabs, Inc.
    • Device Portfolio
    • Shanghai Korain Biotech Co., Ltd
    • Device Portfolio
    • Scent-Sations, Inc.
    • Device Portfolio
    • ZI de la Nau
    • Device Portfolio
    • KOKEN CO., LTD.
    • Device Portfolio
  • アナリストの見解

第10章 セクション

目次

Title:
Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs (Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline) and Fluorescent AGEs (Pentosidine and Methylglyoxal-lysine dimer (MOLD))), by Application (Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, and Others), by End User (Hospitals, Specialty Clinics, and Homecare Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Advanced glycation end products (AGEs), also known as glycotoxins or atherogenic molecules, are the diverse group of highly oxidant compounds. AGEs are formed through a non-enzymatic reaction between reducing sugars and free amino groups of proteins, lipids, or nucleic acids. This reaction is also known as the Maillard or browning reaction. Advanced glycation end products (AGEs) are used to treat pathological conditions such as diabetes mellitus (DM), cardiovascular disease, Alzheimer's disease, cancer, and natural aging. Increasing prevalence of cardiovascular diseases (CVD) is expected to drive growth of the advanced glycation end products market. According to the American Heart Association, 2016, cardiovascular diseases account for 17.3 million deaths every year, globally, where an estimated 23.3 million people are expected to die from CVD by 2030. Such rising prevalence of chronic diseases is expected to drive the advanced glycation end products market growth over the forecast period.

Market Dynamics

Market players are focusing on research and development of advanced glycation end products in diabetic complications as advanced glycation end products (AGEs) are key factor in the development of metabolic memory in diabetic complications, which is expected to drive growth of the global advanced glycation end products market over the forecast period. According to the International Diabetes Federation (IDF), in 2017, the estimated number of 18 to 99 year old diabetic patients was around 425 million globally.

Key features of the study:

  • This report provides in-depth analysis of the global advanced glycation end products market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global advanced glycation end products market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Merck KGaA, Diagnoptics Technologies B.V., Cell Biolabs, Inc., Shanghai Korain Biotech Co., Ltd, Scent-Sations, Inc., Z.I. de la Nau, and KOKEN CO., LTD. among others
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global advanced glycation end products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global advanced glycation end products market

Detailed Segmentation:

  • Global Advanced Glycation End Products Market, By Type:
    • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
    • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
  • Global Advanced Glycation End Products Market, By Application:
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
  • Global Advanced Glycation End Products Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
  • Global Advanced Glycation End Products Market, By Region:
    • North America
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Merck KGaA*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Diagnoptics Technologies B.V
    • Cell Biolabs, Inc.
    • Shanghai Korain Biotech Co., Ltd
    • Scent-Sations, Inc.
    • Z.I. de la Nau
    • KOKEN CO., LTD.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Developments
  • PEST Analysis

4. Global Advanced Glycation End Products Market - Impact of Coronavirus (COVID-19) Pandemic

  • Impact assessment
  • Pre COVID-19 Market Scenario
  • Post COVID-19 Market Scenario
  • Government measures to combat COVID-19

5. Global Advanced Glycation End Products Market, By Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Non-fluorescent AGEs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
  • Fluorescent AGEs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)

6. Global Advanced Glycation End Products Market, By Application, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Diabetic Complications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Bone Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Neurodegenerative Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global Advanced Glycation End Products Market, By End User, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Home Care Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

8. Global Advanced Glycation End Products Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Merck KGaA
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Diagnoptics Technologies B.V.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cell Biolabs, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Shanghai Korain Biotech Co., Ltd
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Scent-Sations, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Z.I. de la Nau
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • KOKEN CO., LTD.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact